Natick-based Boston Scientific Corp. said its second quarter net income increased to $158 million from $98 million a year ago.
The year-ago results included acquisition, divestiture and restructuring charges of $206 million. The most recent quarter’s results include $97 million in asset impairment charges, purchased research and development charges associated with acquisitions and restructuring charges.
Revenue for the quarter rose slightly to $2 billion.
The company said the 61 percent profit growth was spurred by sales increases in both its cardiac rhythm management and stent businesses.
